Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07390123 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 1 → 9 locations Start date changed from estimate of Feb 2026 to Apr 7, 2026v2 Show 1 more changeShow less
    • Start date changed from estimate of Feb 2026 to Apr 7, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
Trial Details
NCT Number NCT07390123
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Conditions IgA Nephropathy (IgAN)
Enrollment 370 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov